Email this page to a friend

SITE REGISTRATION
Registration benefits include:
  • Access to CME/CE programs and certification
  • Additional information from the provider
  • Reminders of new CME/CE activities and related content

About this site
RAoutlook.org is a free educational Web site designed to provide rheumatologists and other health care professionals with the latest information and education on advances in the management of patients with RA.

Now at RAoutlook.org! Point of Care CME- Click Here




WHAT'S NEW

Closing the Gap

Do you currently treat patients who have rheumatoid arthritis and are pregnant?
 Yes
 No
 Unsure

How confident are you in making treatment choices for a pregnant patient with rheumatoid arthritis who requires drug therapy?
 Very confident
 Confident
 Somewhat confident
 Not confident

How likely would you be to participate in an educational activity that addressed management of therapies for rheumatoid arthritis in pregnant patients?
 Very likely
 Likely
 Unlikely
 Would not participate


CME SPOTLIGHT

Optimizing Treatment Outcomes for Patients With Rheumatoid Arthritis
New CME Internet Activity Available!
This CME activity includes case-based scenarios to illustrate management strategies for patients with RA.

Release date: July 2009
Expiration date: July 31, 2010
Estimated time to complete activity:1.75 hours

VIEW ACTIVITY     REQUEST CD-ROM



EXPERT PRACTICE HIGHLIGHT

New Biologic Therapies and Agents in the Pipeline for Rheumatoid Arthritis
Joel M. Kremer, MD
The development of biologic therapies that target specific steps in the pathogenesis of rheumatoid arthritis has allowed clinicians to make great strides in the treatment of patients with this disease. Despite these advances, there remains a need for additional safe and effective rheumatoid arthritis treatments. In this Expert Practice, Dr. Joel M. Kremer of Albany Medical College and The Center for Rheumatology in Albany, New York discussed a number of new biologic agents in development for the treatment of rheumatoid arthritis. He reviewed recent clinical data for these agents and shared his insights on how they may fit into existing treatment paradigms.
READ MORE